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Oxidative stressAbstract Chronic Obstructive Pulmonary Disease (COPD) is a major public health problem. It is the
fourth leading cause of chronicmorbidity andmortality worldwide. COPD is characterized by a specific
pattern of inflammation involving many cells and mediators. Neopterin serves as a marker of systemic
immune activation, which is of importance in the pathogenesis and progression of various diseases.
Aim of the work: This study was conducted to elucidate the role of neopterin in the pathogenesis of
COPD.
Methods: 55 COPD patients and 20 healthy control subjects of similar age and sex were included in
the study. Neopterin levels in the serum and sputum samples were measured in all subjects.
Results: The mean values of neopterin in the serum (20.34 ± 4.70 nmol/l) and sputum (32.07 ±
8.14 nmol/l) samples of COPD patients were significantly higher than the mean values of neopterin
in the serum and sputum samples of control subjects (6.27 ± 3.35 nmol/l and 4.13 ± 2.25 nmol/l
respectively) (p< 0.001). Also, COPD patients with exacerbation had significantly higher
(p< 0.001) serum and sputum neopterin levels (23.47 ± 2.56 nmol/l and 39.94 ± 5.47 nmol/l respec-
tively) in comparison with stable COPD patients (18.69 ± 4.76 nmol/l and 27.91 ±
5.95 nmol/l respectively). There was statistically significant difference (p value < 0.05) between
different COPD severity groups in the mean values of serum and sputum neopterin (nmol/l). There
was statistically significant difference (p value < 0.05) in the mean values of serum and sputum neop-
terin between different COPD patients when they are classified according to the smoking state. Current
smokers have higher mean values of serum (22.40 ± 3.04 nmol/l) and sputum (39.60 ± 7.56 nmol/l)
neopterin than ex smokers (20.33 ± 4.67 nmol/l and 29.84 ± 6.33 nmol/l respectively) and nonsmok-
ers (16.00 ± 5.3 nmol/l and 26.42 ± 6.60 nmol/l respectively).
Conclusions: This study found increased neopterin serum and sputum levels among COPD patients
and suggests a role for neopterin in the pathogenesis of COPD. We recommend larger studies to sup-
port our results.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).rculosis.
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Chronic Obstructive Pulmonary Disease (COPD) is a major
public health problem. It is the fourth leading cause of
chronic morbidity and mortality in the United States, and
is projected to rank fifth in 2020 in burden of disease caused
worldwide, according to a study published by the World
Bank/World Health Organization [1]. COPD is characterized
by a specific pattern of inflammation involving neutrophils,
macrophages, and lymphocytes. These cells release many
inflammatory mediators and interact with structural cells in
the airways and lung parenchyma [2]. A wide variety of
inflammatory mediators that have been shown to be
increased in COPD patients attract inflammatory cells from
the circulation (chemotactic factors), amplify the inflamma-
tory process (proinflammatory cytokines), and induce struc-
tural changes [3].
Neopterin is a catabolic product of guanosine triphos-
phate (GTP), a purine nucleotide. Neopterin belongs to the
chemical group known as pteridines. It is synthesized by acti-
vated monocytes, macrophages, dendritic cells, and endothe-
lial cells upon stimulation with the cytokine interferon-
gamma and to a lesser extent by interferon alpha and beta
with its release being enhanced by tumor necrosis factor
[4,5]. Neopterin serves as a marker of systemic immune
activation. Measurement of neopterin concentrations in body
fluids like blood serum, cerebro-spinal fluid or urine provides
information about cellular immune activation, which is of
importance in the pathogenesis and progression of various
diseases, e.g., in viral infections, in autoimmune or inflamma-
tory diseases, rejection episodes following allograft transplan-
tation, autoimmune-logical diseases and in several malignant
diseases [6,7].
Aim of the work
This study was conducted to elucidate the role of neopterin in
the pathogenesis of COPD.Subjects and methods
This study included 55 patients with COPD (45 men, 10
women) with a mean age of 56.49 ± 8.52 years (ranging 42–78)
that were selected from patients who visited our university
hospitals and 20 healthy control subjects (15 men, 5 women,
mean age 54.37 ± 7.33 years, range 39–74 years) (Table 1).
Patients and control subjects were matched for age and gender.
The COPD patient group included 36 stable COPD patients
and 19 COPD patients with exacerbation.
The diagnosis of COPD was established by clinical symp-
toms, physical examination, chest radiography and pulmonary
function tests according to guidelines of GOLD (2014) [1].
The COPD subjects were classified into (stages I–IV) on the
basis of their post-bronchodilator forced expiratory volume in
one second (FEV1)/forced vital capacity (FVC) and FEV1 %
predicted. FEV1/FVC was <70% and their FEV1 fell into set
bands (stage 1: FEV1P 80%; stage 2: 50%P FEV1 < 80%;
stage 3: 30%P FEV1 < 50%; stage 4: FEV1 < 30%).Stable Chronic Obstructive Pulmonary Disease
Stable COPD is defined by the absence of any exacerbation for
3 months preceding the study [8].
Acute exacerbation of COPD (AECOPD)
The American Thoracic Society (ATS) and European Respira-
tory Society (ERS) define an exacerbation as an acute change
in a patient’s baseline dyspnea, cough, or sputum that is
beyond normal variability, and that is sufficient to warrant a
change in therapy [9].
Methods
All persons included in this study were subjected to the
following:
1. Full history taking.
2. Thorough medical examination.
3. Plain chest radiography (posterio-anterior and lateral).
4. Pulmonary function testing.
5. Complete blood picture (CBC) and differential.
6. CRP.
7. Measurement of neopterin levels in the serum and sputum
samples of COPD patients and control subjects.
Blood samples for laboratory assessments were obtained
from all subjects included in this study. Sera were separated
by centrifugation at 1500 g for 10 min and were frozen at
70 C and protected from light. Sputum samples were also
collected from all included subjects. All COPD patients gave
their sputum samples spontaneously, but control subjects gave
their samples after the induced sputum technique [10]. Sputum
samples were kept in a cold place (temp. 4 C) and processed
within two hours. They were solubilized with DTT (dithiothre-
itol) followed by Dulbecco’s phosphate buffer saline (D-PBS).
Then the mixture was filtered and centrifuged. The super-
natant is aspirated and frozen at 70 C for neopterin
analysis.
Neopterin concentrations were determined in the serum
and sputum samples by the ELISA method using
commercially available kit manufactured by IBL, Hamburg
(Germany) [11].
Results
The mean values of neopterin in the serum (20.34 ±
4.70 nmol/l) and sputum (32.07 ± 8.14 nmol/l) samples of
COPD patients were significantly higher than the mean values
of neopterin in the serum and sputum samples of control sub-
jects (6.27 ± 3.35 nmol/l and 4.13 ± 2.25 nmol/l respectively)
(p< 0.001) (Table 2 and Fig. 1). Also, COPD patients with
exacerbation had significantly higher (p< 0.001) serum and
sputum neopterin levels (23.47 ± 2.56 nmol/l and 39.94
± 5.47 nmol/l respectively) in comparison with stable COPD
patients (18.69 ± 4.76 nmol/l and 27.91 ± 5.95 nmol/l respec-
tively) (Table 3 and Fig. 2).
Table 1 Characteristics of COPD patients and control
groups.
Group Patients Control
No. 55 20
Male/female 45/10 15/5
Age yrs 56.49 ± 8.52 54.37 ± 7.33
FEV1 % pred 51.88 ± 17.52 93.66 ± 5.42
FEV1/FVC % 60.7 ± 5.33 90.75 ± 4.1
PO2 62.54 ± 15.25 95.88 ± 2.70
PCO2 41.10 ± 7.55 39.40 ± 2.62
Smoking
Current 15 0
Ex smoker 33 0
Non smoker 7 20
Severity
I (FEV1 P80% of predicted) 9 (16.36%) –
II (FEV1 P50% and <80%) 16 (29.10%) –
III (FEV1 P30% and <50%) 20 (36.36%) –
IV (FEV1 <30% of predicted) 10 (18.18%) –
Table 2 Mean values of serum and sputum neopterin among
COPD patients and control groups.
Group Serum neopterin
mean values ± SD
(nmol/l)
Sputum neopterin
mean values ± SD
(nmol/l)
p value
COPD
patients
No. = 55
20.34 ± 4.70 32.07 ± 8.14 <0.001
Control
subjects
No. = 20
6.27 ± 3.35 4.13 ± 2.25
0
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Figure 1 Mean values of serum and sputum neopterin among
COPD patients and control groups.
Table 3 Mean values of serum and sputum neopterin among
stable COPD patients and COPD patients with exacerbation.
Group Serum neopterin
mean values ± SD
(nmol/l)
Sputum neopterin
mean values ± SD
(nmol/l)
p value
Stable
COPD No.
= 36
18.69 ± 4.76 27.91 ± 5.95 <0.001
Exacerbated
COPD No.
= 19
23.47 ± 2.56 39.94 ± 5.47
0
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Figure 2 Mean values of serum and sputum neopterin among
stable COPD patients and COPD patients with exacerbation.
Table 4 Mean values of serum and sputum neopterin (nmol/l)
among different COPD severity groups.
Severity Serum neopterin
(nmol/l) (mean ± SD)
Sputum neopterin
(nmol/l) (mean ± SD)
Mild
(No. = 6)
14.50 ± 2.58 24.16 ± 3.06
Moderate
(No. = 19)
20.36 ± 5.34 29.42 ± 7.12
Severe
(No. = 25)
20.92 ± 3.60 34.48 ± 8.36
Very severe
(No. = 5)
24.40 ± 3.20 39.60 ± 0.89
ANOVA F
p value
5.57 6.02
<0.01 <0.01
Role of neopterin among COPD patients 25There was a statistically significant difference (p value <
0.05) between different COPD severity groups in the mean val-
ues of serum and sputum neopterin (nmol/l) (Table 4).
The serum and sputum neopterin levels increased with
increased severity of COPD. There was a significant positive
correlation (p value < 0.001) between COPD severity andserum (r= 0.482) and sputum (r= 0.611) neopterin levels
(Figs. 3 and 4). Also, there is positive correlation between
the serum and sputum neopterin levels (r= 0.679).
There was statistically significant difference (p value
<0.05) in the mean values of serum and sputum neopterin
between different COPD patients when they are classified
according to the smoking state. Current smokers have higher
mean values of serum (22.40 ± 3.04 nmol/l) and sputum
(39.60 ± 7.56 nmol/l) neopterin than ex smokers (20.33 ±
4.67 nmol/l and 29.84 ± 6.33 nmol/l respectively) and
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Figure 3 Mean values of serum neopterin (nmol/l) among
different COPD severity groups.
0
5
10
15
20
25
30
35
40
45
Mild Moderate Severe very severe
Figure 4 Mean values of sputum neopterin (nmol/l) among
different COPD severity groups.
Table 5 Mean values of serum and sputum neopterin (nmol/l)
among COPD patients regarding smoking status.
Group Serum neopterin
(mean ± SD)
Sputum neopterin
(mean ± SD)
p value
Smokers
(No. = 15)
22.40 ± 3.04 39.60 ± 7.56 p< 0.05
Ex smokers
(No. = 33)
20.33 ± 4.67 29.84 ± 6.33
Non smokers
(No. = 7)
16.00 ± 5.35 26.42 ± 6.60
26 A.A. Halim et al.nonsmokers (16.00 ± 5.3 nmol/l and 26.42 ± 6.60 nmol/l
respectively) (Table 5).
Discussion
In this study, the mean values of neopterin in the serum (20.34
± 4.70 nmol/l) and sputum (32.07 ± 8.14 nmol/l) samples of
COPD patients were significantly higher than the mean values
of neopterin in the serum and sputum samples of control sub-
jects (6.27 ± 3.35 nmol/l and 4.13 ± 2.25 nmol/l respectively)
(p< 0.001). Also, COPD patients with exacerbation had
significantly higher (p< 0.001) serum and sputum neopterin
levels (23.47 ± 2.56 nmol/l and 39.94 ± 5.47 nmol/l respec-
tively) in comparison with stable COPD patients (18.69
± 4.76 nmol/l and 27.91 ± 5.95 nmol/l respectively). Other
workers found similar results. Takabatake and his colleagues[12] evaluated circulating levels of interferon-gamma (IFN-
gamma), soluble interleukin-2 receptor (sIL-2R), neopterin,
and soluble intercellular adhesion molecule-1 (sICAM-1) in
35 clinically stable patients with COPD and in 22 age-
matched healthy controls. They found that circulating levels
of sIL-2R (1.52+/ 1.25 vs. 0.97+/ 0.48 ng/ml; p< 0.05),
neopterin (7.23+/ 4.24 vs. 4.95+/ 1.52 nmol/l; p< 0.05),
and sICAM-1 (665+/ 302 vs. 328+/ 164 ng/ml;
p< 0.0001), but not IFN-gamma (7.55+/ 4.72 vs.
6.65+/ 1.13 pg/ml; p=NS) were significantly higher in
patients with COPD than those in the controls. Warwick
et al. [13] detected that, among COPD patients, levels of the
novel markers neopterin and IP-10 were significantly increased
in induced sputum supernatant (pooled groups pre and post
exacerbation: IP-10: 188.6 ± 102.1 vs. 5.40 ± 1.28 pg/ml,
p = 0.006; neopterin: 15.81 ± 2.50 vs. 5.38 ± 0.45 nmol/L,
p < 0.0001), as was TNF-a (137.8 ± 49.64 vs. 71.56 ±
45.03 pg/ml, p = 0.018).
Our study revealed a statistically significant difference
(p value < 0.05) between different COPD severity groups in
the mean values of serum and sputum neopterin (nmol/l).
The serum and sputum neopterin levels increased with
increased severity of COPD. There was a significant positive
correlation (p value < 0.001) between COPD severity and
serum (r= 0.482) and sputum (r= 0.611) neopterin levels.
Also, there is a positive correlation between the serum and
sputum neopterin levels (r= 0. 679). Our findings are in
agreement with that of others. Garrod et al. [14] found that
measures of systemic inflammation (neopterin, TNF-a, IL6,
and in particular CRP) are correlated with COPD severity in
primary care.
We detected a statistically significant difference
(p value < 0.05) in the mean values of serum and sputum
neopterin between different COPD patients when they are
classified according to the smoking state. Current smokers
have higher mean values of serum (22.40 ± 3.04 nmol/l) and
sputum (39.60 ± 7.56 nmol/l) neopterin than ex smokers
(20.33 ± 4.67 nmol/l and 29.84 ± 6.33 nmol/l respectively)
and nonsmokers (16.00 ± 5.3 nmol/l and 26.42 ± 6.60 nmol/l
respectively). Other researchers revealed similar results.
Djordjevic et al. [15] found a strong correlation between
neopterin and both smokers (p< 0.01).
Oxidative stress induced by reactive oxygen and nitrogen
species (ROS and RNS) plays a central role in the pathophys-
iolgy of COPD [16]. Previous data indicate a possible partici-
pation of neopterin derivates within the cytotoxic mechanism
of white blood cells [17]. On the one hand, a strong correlation
between detection of neopterin and ability of monocytes/
macrophages/neutrophils to set free reactive oxygen species
[18] was found. Thus, neopterin determination can be consid-
ered as an indirect marker for the amount of immunologically
induced oxidative stress. On the other hand, neopterin
derivates are able to influence the effects of reactive oxygen,
nitrogen and chlorine species. It was demonstrated that neop-
terin is a potent enhancer of various reactive substances, such
as H2O2, HOCl, chloramine and peroxynitrite (ONOO-, an
effector molecule of nitric oxide radical, NO), while 7,8-
dihydroneopterin is mainly acting as a scavenger [17,18].
Neopterin derivates seem to be able to also interfere with
molecular biological pathways that are regulated by
redox-balances in general. In vitro, derivatives of neopterin
induce expression of the nuclear factor-jB [19–21] and of the
Role of neopterin among COPD patients 27iNOS-gene [22]. Similar to this, programed cell death, apopto-
sis, is induced or intensified by neopterin derivates [23–27].
These findings suggest a new role for neopterin in the
pathogenesis of COPD. Previous reports show that neopterin
and 7,8-dihydroneopterin upregulate expression of proto-
oncogene c-fos, so these substances may be even involved in
malignant transformation of cells [28,29].
Conclusions
This study found increased neopterin serum and sputum levels
among COPD patients and suggests a role for neopterin in the
pathogenesis of COPD. We recommend larger studies to
support our results.
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